Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Fertirelin vs Gonadorelin (GnRH) — Peptide Comparison

At a Glance Quickcomparison Dose Range Fertirelin 25 micrograms–100 micrograms mg Gonadorelin (GnRH) 0.1-1.5–3-10 mg Frequency Once daily Administration Intramuscular injection Subcutaneous injection Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 we

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Fertirelin

25 micrograms–100 micrograms mg

Gonadorelin (GnRH)

0.1-1.5–3-10 mg

Frequency

Once daily

Administration

Intramuscular injection

Subcutaneous injection

Cycle Length

Ongoing/indefinite

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Moderate human trials (Phase 1-2)

Efficacy

Benefitratings

Reproductive Synchronization

Hormone Support

Veterinary Breeding Enhancement

Reproductive Health

Hormone Balance

Ovulation Support

Technical Data

Compoundspecifications

Molecular Formula

C55H76N16O12

Molecular Weight

1153.3 g/mol

Half-Life

Variable depending on formulation; sustained-release formulations extend duration

Bioavailability

High when administered via injection

CAS Number

66002-66-2

C55H75N17O13

1182.3

2-4 minutes

Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)

34973-08-5

Protocols

Dosingtiers

standard

50-100 mcg per animal

Single injection at the defined point in the synchronization protocol

Single dose (repeated per breeding cycle as needed)

Fertirelin is a veterinary GnRH agonist. In dairy cattle, 50 mcg and 100 mcg intramuscular both triggered an LH surge and comparable conception rates for ovulation synchronization and fixed-time insemination [4]. Used to induce ovulation and improve conception in cattle [1].

100 mcg

Single dose

One-time diagnostic test

FDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].

5 mcg per pulse (range 1-20 mcg)

Every 90 minutes via pulsatile pump

One or more ovulatory cycles; reassessed at 21-day intervals

FDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.

Applications

Bestsuited for

Livestock breeding programs

Fertirelin is particularly well-suited for individuals focused on livestock breeding programs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reproductive synchronization in cattle

Fertirelin is particularly well-suited for individuals focused on reproductive synchronization in cattle. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Fertility enhancement in veterinary settings

Fertirelin is particularly well-suited for individuals focused on fertility enhancement in veterinary settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Research on reproductive hormone mechanisms

Fertirelin is particularly well-suited for individuals focused on research on reproductive hormone mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Improving fertility and conception chances

Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Regulating irregular menstrual cycles

Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Enhancing reproductive hormone levels

Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting natural pregnancy attempts

Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Mild discomfort at treatment site

Transient hormone fluctuations

Temporary behavioral changes in animals

Mild injection site reactions

Short-term changes in appetite

Temporary mood variations

Minimal systemic effects at therapeutic doses

Uncommon

Occasional swelling at injection site

Serious

Severe allergic reaction

Mild headache

Local injection site reactions (redness, swelling)

Temporary hot flashes

Mood changes or emotional sensitivity

Nausea or mild stomach upset

Allergic skin reactions

Dizziness or lightheadedness

Temporary changes in vision

Joint or muscle aches

Insomnia or sleep disturbances

Severe allergic reactions (difficulty breathing, swelling)

Severe hormonal imbalance symptoms

Ovarian hyperstimulation syndrome (OHSS)

Signs of blood clots (chest pain, leg swelling)

Severe mood changes or depression

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Fertirelin is a GnRH agonist developed specifically for veterinary use in livestock, particularly cattle breeding and fertility management. The peptide has been safely used in veterinary medicine for over 40 years with a well-documented safety profile in animals. Important limitation: Fertirelin is NOT approved for human use. All safety and efficacy data comes from veterinary applications in cattle and limited laboratory research. Human safety data is minimal and extrapolation from veterinary use is problematic. The biphasic response (initial hormone surge followed by suppression) must be carefully managed in any application. Individual responses can vary significantly based on age, hormonal status, and concurrent medications.

Contraindications

xPregnancy (may disrupt existing pregnancy)

xHypersensitivity to GnRH analogs

xActive reproductive infections

xConcurrent use with certain medications

xUndiagnosed reproductive disorders

FDA approved for this use

Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.

xPregnancy or breastfeeding

xHormone-sensitive cancers (breast, prostate, ovarian)

xSevere pituitary or hypothalamic disease

xUndiagnosed abnormal vaginal bleeding

xKnown hypersensitivity to GnRH

Decision Guide

Which isright for you?

Choose Fertirelin if...

Livestock breeding programs

Reproductive synchronization in cattle

Fertility enhancement in veterinary settings

Research on reproductive hormone mechanisms

Choose Gonadorelin (GnRH) if...

Improving fertility and conception chances

Regulating irregular menstrual cycles

Enhancing reproductive hormone levels

Supporting natural pregnancy attempts

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status FDA approved for this use Safety Overview Aprepitant (the primary NK1 antagonist) has been FDA-approved since 2003 with extensive safety data in over 50,000 cancer patients receiving highly emetogenic chemotherapy. Most common adverse events are mild to moderate—headache (15-20%), fatigue, and constipation—which are often difficult to attribute solely to aprepitant versus underlying malignancy or chemotherapy effects. Serious but rare adverse events include Stevens-Johnson syndrome (extremely uncommon) and QT prolongation (in susceptible individuals), requiring baseline ECG evaluation in high-risk patients. Contraindications xSevere hypersensitivity to aprepitant or any component xConcurrent use with certain other medications that affect the liver xSevere cardiac conditions Research compound KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption. xNot approved for human clinical use xUnknown interactions with immunosuppressive medications xInsufficient safety data for pregnancy and lactation xPotential melanocortin receptor effects in susceptible individuals Decision Guide

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →